美国食品药品监督管理局（FDA）已正式授予辉瑞公司Braftovi联合疗法完全批准，该疗法将作为转移性结直肠癌的一线治疗方案。此次全面批准标志着该组合疗法在临床应用中迈出关键一步，为患者提供了新的治疗选择。
美国食品药品监督管理局（FDA）已正式授予辉瑞公司Braftovi联合疗法完全批准，该疗法将作为转移性结直肠癌的一线治疗方案。此次全面批准标志着该组合疗法在临床应用中迈出关键一步，为患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.